Over the last 7 days, the United States market has risen 2.1%, contributing to a notable 14% climb over the past year, with earnings expected to grow by 15% annually. In this favorable environment, ...

Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...

Merck’s stock fell 1.77% to $80.93 while the market gained, despite rising 5.26% over the past month. The company’s upcoming ...

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its ...

The stock's fall snapped a four-day winning streak.

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

UBS reaffirmed its Buy rating and $105 target for Merck, brushing off investor pessimism about the pharmaceutical giant’s ...

Merck KGaA has synthesized transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or TAZ/TEAD interaction inhibitors reported to be useful for the treatment of cancer.

Have you or someone you love been diagnosed with Alzheimer’s disease? This clinical trial may be just what you.